IJIMM, Volume 4, Issue 03, 2026 ISSN: 2995-5319
http://medicaljournals.eu/index.php/IJIMM/issue/view/3
INTERNATIONAL JOURNAL OF INTEGRATIVE AND MODERN MEDICINE

The Role of Early Vaccination in Preventing Neonatal Infectious Diseases: A Review

Tukhtaeva Umida Dilmurodovna
Tashkent State Medical university, Assistant of the Department Neonatology
umidaxon0307@mail.ru, https://orcid.org/0000-0002-8522-9239

Mirzayeva Farangiz Normurod qizi
Tashkent State Medical university, bachelor's degree.
mirzayevafarangiz53@gmail.com

Urinova Umida Uktam kizi
Toshkent State Medical University
umidaurinova721@gmail.com

Abstract: Neonatal infectious diseases remain an important cause of early-life morbidity and mortality. In Uzbekistan, improvements in maternal and child healthcare have enhanced neonatal survival; however, conditions such as neonatal sepsis, hepatitis B vertical transmission, and tuberculosis exposure continue to pose challenges. Early vaccination, administered at birth or during the first weeks of life, is a key preventive strategy. This review analyzes national epidemiological data from 2022 to 2024 to evaluate the impact of early immunization on neonatal infectious disease incidence in Uzbekistan. The study focuses on BCG vaccination, hepatitis B birth-dose coverage, and maternal tetanus immunization. The findings show a consistent decline in neonatal infectious disease rates over the three-year period, alongside vaccination coverage levels exceeding 95%. Reductions in perinatal hepatitis B transmission and sustained elimination of neonatal tetanus highlight the effectiveness of timely immunization and strengthened perinatal care. Overall, early vaccination remains a cornerstone of neonatal infection prevention in Uzbekistan, contributing significantly to improved health outcomes and reduced infectious morbidity.

Keywords: Early vaccination; Neonatal infectious diseases; Uzbekistan; Immunization coverage; BCG vaccine; Hepatitis B birth dose; Maternal immunization; Neonatal sepsis; Public health prevention; Vertical transmission; Tuberculosis prevention; Epidemiological trends.

Introduction

Neonatal infectious diseases remain a major public health concern worldwide and continue to contribute significantly to infant morbidity and mortality, particularly within the first 28 days of life. The neonatal period represents a uniquely vulnerable stage of human development characterized by immunological immaturity, incomplete adaptive immune responses, and increased susceptibility to bacterial and viral pathogens[1]. Although substantial progress has been achieved globally in reducing neonatal mortality rates, infectious causes still account for a considerable proportion of early-life deaths, especially in low- and middle-income countries. In Uzbekistan, comprehensive healthcare reforms implemented over the past two decades have markedly improved maternal and neonatal outcomes. The expansion of perinatal centers, modernization of neonatal intensive care units, and strengthening of primary healthcare services have contributed to declining infant

mortality indicators[2]. Nevertheless, infectious conditions such as neonatal sepsis, pneumonia, hepatitis B virus (HBV) transmission, and tuberculosis exposure continue to pose clinical challenges. Preventive strategies remain central to sustaining further improvements in neonatal health. Vaccination is recognized as one of the most effective and cost-efficient public health interventions in modern medicine. Early vaccination—defined as immunization administered at birth or during the first weeks of life—provides active immunological protection during a period of heightened vulnerability. In Uzbekistan, the National Immunization Program includes the Bacillus Calmette–Guérin (BCG) vaccine administered at birth for tuberculosis prevention, as well as the hepatitis B birth dose vaccine given within the first 24 hours of life to prevent vertical transmission. Additionally, maternal immunization against tetanus during pregnancy plays a critical role in preventing neonatal tetanus[3]. The biological basis for early vaccination lies in neonatal immune priming. Although neonatal immune systems are not fully mature, they are capable of generating antigen-specific responses when appropriately stimulated. Early exposure to vaccine antigens promotes the development of adaptive immunity, while certain vaccines—such as BCG—have been shown to induce trained innate immunity, enhancing non-specific defense mechanisms against various pathogens. This immunomodulatory effect may provide broader protection beyond the targeted disease. Maintaining high vaccination coverage is particularly important in Uzbekistan due to demographic factors, internal migration, and regional variations in healthcare accessibility[4]. Rural areas may face logistical challenges related to vaccine delivery and perinatal follow-up, underscoring the need for consistent public health monitoring. Evaluating recent epidemiological trends over a defined period allows for assessment of vaccination program effectiveness and identification of areas requiring strategic improvement. This review aims to analyze the role of early vaccination in preventing neonatal infectious diseases in Uzbekistan from 2022 to 2024. By integrating epidemiological data, immunization coverage statistics, and immunological principles, the study seeks to evaluate the protective impact of early-life vaccination and its contribution to national neonatal health outcomes[5].

Materials and Methods

This study represents a retrospective analytical review evaluating the impact of early vaccination on neonatal infectious disease trends in Uzbekistan over a three-year period (2022–2024). The analysis was conducted using nationally reported epidemiological and immunization coverage data[6].

Data were obtained from official public health and statistical sources, including:

- Annual reports of the Ministry of Health of the Republic of Uzbekistan
- National Immunization Program coverage reports (2022–2024)
- Maternal and neonatal morbidity statistics from regional perinatal centers
- Publicly available WHO and UNICEF country immunization estimates for Uzbekistan

The data included nationwide aggregated indicators rather than individual patient-level records. The study population consisted of all live-born neonates in Uzbekistan between January 1, 2022, and December 31, 2024. Neonatal infectious disease data were analyzed within the first 28 days of life[7].

The following conditions were included in the analysis:

- Neonatal sepsis (early- and late-onset)
- Neonatal pneumonia of infectious origin
- Perinatal hepatitis B transmission
- Neonatal tetanus (if reported)
- Documented early tuberculosis exposure in neonates

Vaccination indicators included:

- BCG vaccination coverage at birth
- Hepatitis B birth dose coverage within 24 hours
- Maternal tetanus immunization coverage during pregnancy

Descriptive statistical methods were used to evaluate annual changes in neonatal infectious disease incidence between 2022 and 2024. Incidence rates were assessed per 1,000 live births where available[8]. Year-to-year percentage change was calculated using the formula:

Percentage Change=(Valuecurrent−Valueprevious)Valueprevious×100\text{Percentage Change} = \frac{(Value_{current} - Value_{previous})}{Value_{previous}} \times 100Percentage Change=Valueprevious(Valuecurrent−Valueprevious)×100

Result and Discussion

Correlation analysis was performed to assess associations between vaccination coverage rates and neonatal infection incidence trends. Statistical trends were interpreted descriptively due to the aggregate nature of the data. This study utilized publicly available aggregated national health data and did not involve direct patient contact or identifiable personal information[9]. Therefore, formal ethical approval was not required. Analysis of national immunization reports between 2022 and 2024 demonstrates consistently high early vaccination coverage across Uzbekistan. The Bacillus Calmette–Guérin (BCG) vaccine administered at birth maintained coverage levels above 96% throughout the observed period. Similarly, hepatitis B birth-dose vaccination coverage remained stable, ranging between 95% and 97%. Maternal tetanus immunization coverage during pregnancy exceeded 94% nationwide, contributing to sustained elimination of neonatal tetanus cases[10]. Table 1 summarizes national early vaccination coverage rates over the three-year period.

Table 1. Early Vaccination Coverage in Uzbekistan (2022–2024)

Year	BCG at Birth (%)	Hepatitis B Birth Dose (%)	Maternal Tetanus Coverage (%)
2022	96.1	95.4	94.7
2023	96.8	96.2	95.3
2024	97.2	96.9	96.1

The gradual increase in vaccination coverage reflects improvements in perinatal service accessibility, strengthened cold-chain logistics, and enhanced monitoring within primary healthcare facilities[11]. These consistently high coverage rates are critical in preventing vertical and early postnatal transmission of infectious diseases. National epidemiological data demonstrate a progressive decline in reported neonatal infectious disease cases during the study period. The total number of reported neonatal infectious cases per 1,000 live births decreased as follows:

- 2022: 14.8 cases per 1,000 live births
- 2023: 13.2 cases per 1,000 live births
- 2024: 11.9 cases per 1,000 live births

This represents:

- A 10.8% reduction from 2022 to 2023
- A further 9.8% reduction from 2023 to 2024
- An overall 19.6% decline over the three-year period

Figure 1. Trend in Neonatal Infectious Disease Incidence in Uzbekistan (2022–2024)



Figure 1. Three-year decline in reported neonatal infectious disease incidence in Uzbekistan, demonstrating a 19.6% overall reduction between 2022 and 2024.

The most significant reductions were observed in:

- Perinatal hepatitis B transmission
- Severe neonatal tuberculosis-related complications
- Vaccine-preventable bacterial infections

Neonatal tetanus cases remained either absent or sporadic, reflecting effective maternal immunization strategies[12]. The observed decline in neonatal infectious diseases correlates strongly with sustained high vaccination coverage. The hepatitis B birth dose vaccine is particularly critical in preventing vertical transmission from HBsAg-positive mothers. With timely administration within the first 24 hours, the risk of chronic infection decreases dramatically. Similarly, BCG vaccination at birth plays a key role in preventing disseminated tuberculosis and tuberculous meningitis in infants[13]. Although BCG does not prevent infection entirely, it significantly reduces severe disease forms, thereby lowering neonatal morbidity. Maternal tetanus immunization prevents toxin-mediated neonatal tetanus by enabling transplacental antibody transfer. The near-elimination of neonatal tetanus in Uzbekistan reflects the success of this strategy. It is important to note that reductions in neonatal infection rates cannot be attributed to vaccination alone[14]. Improvements in:

- Sterile delivery practices
- Early breastfeeding initiation
- Neonatal intensive care quality
- Infection control protocols

have also contributed to declining incidence. However, vaccination remains the primary preventive intervention targeting specific infectious etiologies. The nearly 20% reduction in neonatal infectious

disease incidence over three years represents a significant public health achievement. Considering Uzbekistan's annual birth rate, this reduction translates into thousands of prevented infection cases annually. Sustained vaccination coverage above 95% is essential to maintaining herd immunity and preventing outbreaks. Even small declines in immunization rates could result in resurgence of vaccine-preventable diseases. The data support the conclusion that early vaccination remains a cornerstone of neonatal infectious disease prevention in Uzbekistan and continues to produce measurable epidemiological benefits[15].

Conclusions

The analysis of national data from Uzbekistan between 2022 and 2024 shows a steady decline in neonatal infectious disease incidence. During this three-year period, infection rates decreased consistently while early vaccination coverage remained high. These findings indicate that early immunization plays a significant role in protecting newborns from preventable infectious diseases. The sustained coverage of BCG and hepatitis B birth-dose vaccination above 95% appears to be associated with the observed reduction in neonatal infections. The decrease in perinatal hepatitis B transmission and the continued absence of neonatal tetanus cases further support the effectiveness of timely immunization strategies. Early vaccination provides protection during the most vulnerable stage of life, when neonatal immune defenses are not yet fully developed. By ensuring immunization within the first hours and days after birth, the healthcare system reduces the risk of severe infection and long-term complications. Although improvements in neonatal care, infection control practices, and maternal health services have also contributed to better outcomes, vaccination remains the primary preventive measure directly targeting infectious pathogens. In conclusion, early vaccination continues to be a cornerstone of neonatal health policy in Uzbekistan. Maintaining high immunization coverage and ensuring timely administration of birth-dose vaccines are essential for sustaining progress in reducing neonatal infectious diseases.

References

1. World Health Organization. Newborns: improving survival and well-being. Geneva: WHO; 2023.
2. United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Levels and Trends in Child Mortality 2023. New York: UNICEF; 2023.
3. World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023.
4. World Health Organization. Hepatitis B vaccines: WHO position paper – July 2017. Weekly Epidemiological Record. 2017;92(27):369–392.
5. World Health Organization. Immunization Agenda 2030: A Global Strategy to Leave No One Behind. Geneva: WHO; 2020.
6. UNICEF. State of the World's Children 2023: For Every Child, Vaccination. New York: UNICEF; 2023.
7. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology. 2021;21(2):83–100.
8. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the neonatal immune response to vaccination. Nature Reviews Immunology. 2017;17(5):311–322.
9. Higgins JPT, Soares-Weiser K, López-López JA, et al. Association of BCG, DTP, and measles vaccines with childhood mortality: systematic review. BMJ. 2016;355:i5170.
10. Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus elimination: progress and challenges. Lancet. 2007;370(9603):1947–1959.
11. Centers for Disease Control and Prevention (CDC). Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Washington DC: CDC; 2021.

12. WHO-UNICEF Estimates of National Immunization Coverage (WUENIC). Uzbekistan country data, 2024 update. Geneva: WHO; 2024.
13. Ministry of Health of the Republic of Uzbekistan. National Immunization Program Annual Report 2022. Tashkent; 2023.
14. Ministry of Health of the Republic of Uzbekistan. National Immunization Program Annual Report 2023. Tashkent; 2024.
15. Ministry of Health of the Republic of Uzbekistan. Neonatal Morbidity and Mortality Statistical Bulletin 2024. Tashkent; 2025.